NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial

Germany’s Federal Institute for Drugs and Medical Devices (BfArM) approved the Company’s (NRSN) Clinical Trial Application (CTA) to enroll patients in PARADIGM, its Phase 2b study of its lead combination drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS).

Share:

Join Our Newsletter

Skip to content